Psychedelic News2023-08-08T14:20:44+02:00

News and Press Releases

  • With Appointment of Dr. Dan J. Stein

Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein

March 26, 2025|

Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has announced that it has expanded its newly created Scientific Advisory Board (SAB) with the addition of Dr. Dan J. Stein, a recognized leader in the field of psychopharmacology.

  • Scientific Advisory Board_1

Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board

March 11, 2025|

Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has announced that it will work closely with Albert P. Garcia-Romeu, Ph.D., to chair and develop its newly created Scientific Advisory Board (SAB).

Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

December 7, 2024|

Psyence Group hereby announces that it has entered into an addendum to the previously announced debt-for-equity swap agreements (the "Debt Swap Agreements") with its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), pursuant to which Psyence Biomed has agreed to issue to the Company 337,750 Psyence Biomed common shares at a deemed price of US$3.88 per common share, in exchange for the discharging of the balance of Psyence Biomed's obligations due under the Debt Swap Agreements and a promissory note, dated January 25, 2024, issued by Psyence Biomed to the Company in connection with Psyence Biomed's listing of its common shares on the NASDAQ in January 2024.

Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

October 25, 2024|

Empax Center brings significant expertise in clinical trial execution for mental health and neurological conditions. Psyence Biomed on track to begin recruitment this quarter, and to announce Adjustment Disorder topline data in the second half of 2025

Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs

September 20, 2024|

Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) (as seller), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, today announced that it has entered into a conditional share sale agreement with its NASDAQ-listed associate, Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed" or "PBM") (as purchaser) for the disposal by Psyence Group of its 11.13% stake in privately-held PsyLabs, a company focused on the production of psychedelic active pharmaceutical ingredients (APIs) and extracts for use in research, clinical trials and drug development ("Proposed Transaction"). Per the terms of the Proposed Transaction,

News and Press Releases

Psyence In The News

Psyence wins ISO certification from
British Standards Institute for
psilocybin production facility
Psyence Group’s functional mushroom brand
to be sold in South Africa’s
largest coffee retail chain
Psyence Group begins trading on the
OTCQB platform in New York
to satisfy investor demand
Psyence Group launches its functional
mushroom products under the
GOODMIND banner in South Africa
In this interview with Proactive Investors, Dr. Neil Maresky
talks about his appointment as
CEO of Psyence Group.
Psyence Group ‘delighted’ to reach
psilocybin product development
agreement with Jamaican government

Market For Psychedelic Drugs Expected to Reach $6.9 Billion By 2027

Psychedelic Finance chats to Psyence CEO Jody Aufrichtig

Psyence looking to be a major player
in psychedelics using their federally
licensed facilities
Jody Aufrichtig in conversation
with the CSE’s
Barrington Miller
Go to Top